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Background. To assess if the variants of (R)-alpha-methyl-CoA racemase (AMACR) gene would be associated with the risk of
sporadic prostate cancer in ethnically homogenous Koreans.Materials and Methods. We enrolled 194 patients with prostate cancer
and 169 healthy controls. A total of 17 single nucleotide polymorphisms of the AMACR gene were selected. The distribution of
each genotype and haplotype was analyzed and their association with the incidence of prostate cancer was evaluated. Further, we
detected AMACR expression in tumor with immunohistochemistry and analyzed its association with genotype regarding prostate
cancer risk. Results. AG or GG genotype of rs2278008 (E277K) tended to lower prostate cancer risk. The minor G allele was found
to be a significant allele that decreased the risk of prostate cancer (adjusted OR, 0.57; 95% CI, 0.35–0.93, 𝑃 value = 0.025). In
patients expression AMACR, AG or GG genotype was also significant genotype in terms of prostate cancer risk (adjusted OR, 0.47;
95% CI, 0.26–0.87, 𝑃 value = 0.017). Further, [GGCGG] haplotype consisted of five coding SNPs of rs2278008, rs34677, rs2287939,
rs10941112, and rs3195676 which decreased the risk of prostate cancer (𝑃 value = 0.047). Conclusions. Genetic variations of AMACR
are associated with the risk of sporadic prostate cancer that underwent radical prostatectomy in Koreans.
1. Background
The detailed etiology of prostate cancer is still unclear; it is a
very heterogeneous disease due to the involvement of various
inherited genetic elements and environment factors, includ-
ing a fatty diet. Many studies have sought to identify the
risk factors of prostate cancer, mainly by a targeted gene
approach, which has confirmed the effect of known car-
cinogenesis genes [1–4]. Recently, many studies including
genome-wide association studies (GWAS) identified signif-
icant associations between lots of single nucleotide poly-
morphisms (SNPs) and prostate cancer [5–9]. Some studies
identified chromosome 5p13, the site of the gene encoding
(R)-alpha-methyl-CoA racemase (AMACR), as the location
of a prostate cancer susceptibility gene [10–12].
AMACR is catalytically involved in fatty acid oxidation,
which converts (R)-alpha-methyl-branched-chain fatty acyl-
CoA ester to the (S)-stereoisomer. AMACR is critical in
prostate cancer cell progression; the downregulation of
AMACR expression hampers the proliferation of the LAPC-
4 androgen-responsive prostate cancer cells [13]. AMACR is
abundantly expressed and is recognized as a standard tissue
biomarker capable of a highly sensitive and specific diagnosis
of prostate cancer [14–16]. An AMACR spliced variant was
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reported capable of creating a novel transcript that is
expressed with other forms of AMACR in prostate cancer
[17]. These findings point to the value of AMACR and its
variants in developing diagnostic biomarkers that will com-
plement the diagnostic capability of PSA, while addressing
the limitations of PSA, specifically its low specificity. The
chromosomal region of AMACR has been validated as a
susceptible locus for prostate cancer, including hereditary
prostate cancer [10, 11]. Studies addressing the potential link-
age between AMACR polymorphisms and sporadic prostate
cancer risk in different populations, however, have not been
consistent and have precluded any definitive conclusion [18–
20]. The genetic heterogeneity of ethnically different study
populations might have lead to these inconsistent results.
This study was designed to assess whether genetic variations
of AMACR were associated with sporadic prostate cancer
development in Korean men, known to be an ethnically
homogenous population [21], by investigating the impact of
AMACR polymorphisms on the risk of prostate cancer and
clinical features.
2. Materials and Methods
2.1. Study Subjects. The investigation was a hospital-based
case-control study of prostate cancer. Both prostate cancer
patients and controls were of the same Korean ethnic origin
with all residents born in Korea. Any subject who had any rel-
ative with a past history of prostate cancer among their first-
degree relatives was excluded. Patients who were histologi-
cally confirmed to have prostate cancer were enrolled at the
National Cancer Center in Korea between January 2005 and
February 2009. Controls were confirmed to be free of prostate
cancer by determination of the blood PSA level and by digital
rectal examination. Although the PSA level of three controls
continually increased and exceeded 4 ng/mL, prostate nee-
dle biopsy conducted in the three subjects confirmed the
absence of prostate cancer. All patients underwent radical
prostatectomy and Gleason grading was determined with
prostatectomy specimens. Demographic and clinical data
were based on prostate cancer database in our institution.We
obtained the written informed consent for participation in
the study from all participants. This study was approved by
the Institutional Review Board of the National Cancer Center
in Korea (NCCNCS05-049).
2.2. Single Nucleotide Polymorphism (SNP) Selection and
Genotyping. The target SNPs of AMACR were selected in
the National Center for Biotechnology Information (NCBI)
database version (http://www.ncbi.nlm.nih.gov/projects/
SNP/). We collected the information of all coding SNPs in
AMACR with heterozygosity > 0; a total of 17 SNPs were
identified (see Supplemental Table 1 available online at
http://dx.doi.org/10.1155/2013/394285). From these, four
SNPs with a heterozygosity of 0.5 were excluded. Additional
two SNPs (rs76184600 and rs117220551) were also excluded
because of assay design failure to create suitable primers.
Finally, primers for 11 SNPs were designed using DESINGER
(Sequenom, CA, USA) software (Supplemental Table 2).
GenomicDNAwas prepared from200𝜇L of peripheral blood
using the QIAamp Blood Kit (QIAGEN, Valencia, CA, USA)
according to the manufacturer’s instructions. Genotyping
was performed by the previously described method [1] and
the resulting genotype data were obtained by Typer (version
4.0, Sequenom) and were subjected to statistical analysis.
2.3. AMACRExpression in Prostate Cancer. At least three core
tissue biopsies (each 3mm indiameter)were taken frommor-
phologically representative regions of each paraffin embed-
ded prostate tumor and precisely arrayed using a custom
built instrument. To identify AMACR protein expression,
4 𝜇m thick tissue sections were placed on glass slides for
histological examination, one slide for staining with hema-
toxylin/eosin and the other slide for immunostaining with
anti-AMACR antibody. On the basis of histological analysis,
expression of AMACR protein in each patient was deter-
mined in a blinded fashion by a single experienced pathol-
ogist. Slides were scored by a semiquantitative method. The
intensity of AMACR expression was graded on a score of 0 to
3+ (0 = no staining, 1+ = weakly positive, 2+ = positive, and
3+ = strongly positive).
2.4. Statistical Analyses. The demographic and clinical char-
acteristics in the study population and controls were analyzed
using a chi-square test for categorical variables and an
independent 𝑡-test for continuous variables. Hardy-Weinberg
equilibrium (HWE) was determined separately in cases and
controls for each SNP. SNPs that deviated from the HWE
in the control group were excluded (𝜒2 test at 𝑃 value
<0.05). The association between AMACR polymorphisms
and prostate cancer risk was evaluated on the basis of geno-
typic frequencies of each SNP using an unconditional logistic
regression model. The Cochran-Armitage trend test was
also used to analyze the linear trend, as expressed by odds
ratios (ORs). The haplotype estimation was carried out
using the PHASE program (version 2.1; http://stephenslab
.uchicago.edu/software.html#phase), which implements a
Bayesian statistical method for reconstructing haplotypes.
An unconditional logistic regression determined the associa-
tion between AMACR haplotypes and prostate cancer risk,
considering the haplotypic frequencies of each haplotype
and the haplotype pair of each person. Additionally, the
associations between genotypes and clinical parameters were
determined using an unconditional logistic regression. To
assess the power for detecting association, we used the
power for genetic association analyses (PGA) [22]. All other
statistical analyses were performed using SAS (version 9.1
SAS Institute,NC,USA).The reported𝑃 values are two-sided,
and a significance level < 5% was considered statistically
significant.
3. Results
3.1. Subjects Characteristics. Demographic and clinical char-
acteristics of 194 prostate cancer patients and 169 controls
are summarized in Table 1. Statistically significant differences
between cases and controls were evident with respect to age,
serum PSA level, and drinking status. Most of the prostate
cancer patients displayed a high serum PSA level, with
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Table 1: Demographic and clinical characteristics of the subjects.
Variables Cases (𝑛 = 194) Controls (𝑛 = 169) P valuea
Age, years (median) 66.52 ± 7.16 (68.0) 60.13 ± 3.30 (61.0) <0.001
Serum PSA, ng/mL (median) 21.28 ± 28.15 (9.8) 1.47 ± 1.63 (1.0) <0.001
Serum PSA (ng/mL), no. <0.001
<4 11 (5.7%) 160 (94.7%)
4–10 (≥4 to <10) 87 (44.9%) 8 (4.7%)
10–20 (≥10 to <20) 43 (22.2%) 1 (0.6%)
≥20 53 (27.3%) 0 (0.0%)
BMI, kg/m2 (median) 24.35 ± 2.60 (24.1) 24.42 ± 2.34 (24.2) 0.800
BMI, no. 0.388
<25 127 (65.5%) 102 (61.1%)
≥25 67 (34.5%) 65 (38.9%)
Smoking, pack years (median) 21.93 ± 21.75 (18.3) 19.24 ± 20.60 (14.9) 0.264
Smoking status, no. 0.672
Never 52 (26.8%) 42 (24.9%)
Ever 142 (73.2%) 127 (75.2%)
Drinking status, no. 0.002
Never 68 (35.1%) 34 (20.1%)
Ever 126 (65.0%) 135 (79.9%)
Hypertension, no. 0.502
No 120 (61.9%) 109 (65.3%)
Yes 74 (38.1%) 58 (34.7%)
Family history of prostate cancer† 0.132
No 186 (95.9%) 146 (98.6%)
Yes 8 (4.1%) 2 (1.4%)
Gleason score, no.
2–6 99 (51.0%)
7 62 (32.0%)
8–10 33 (17.0%)
pTstage, no.
pT0 6 (3.1%)
pT2a 37 (19.1%)
pT2b 3 (1.6%)
pT2c 89 (45.9%)
pT3a 31 (16.0%)
pT3b 28 (14.4%)
Immunohistochemistry of AMACR Serum PSA, ng/mL P valuea
<4 4–10 (≥4 to <10) 10–20 (≥10 to <20) ≥20
0 (no staining) 1 (2.6%) 10 (25.6%) 7 (18%) 21 (53.9%)
0.0041+ (weakly positive) 0 (0%) 16 (47.1%) 9 (26.5%) 9 (26.5%)
2+ (positive) 5 (9.1%) 25 (45.5%) 12 (21.8%) 13 (23.6%)
3+ (strongly positive) 5 (7.7%) 36 (55.4%) 15 (23.1%) 9 (13.9%)
PSA: prostate specific antigen; BMI: body mass index; no.: number; AMACR: (R)-alpha-methyl-CoA racemase.
aPearson’s 𝜒2 test for categorical variables and independent t-test for continuous variables; two-sided P-values.
†“Family” represents relatives with the exception of first-degree relative, excluding 21 persons with missing values in the control group.
the risk increasing with age, as expected. No significant dif-
ferences were found in smoking status, body mass index, or
hypertension (Table 1).
3.2. AMACR Polymorphisms and Prostate Cancer Risk. Gen-
otype frequencies for all of the target SNPs of AMACR in
this study are presented in Supplemental Table 3. From 11
cSNPs, one SNP failed during the data quality control process
because of high primer-dimer potential. Five cSNPs were
revealed to be monomorphic for the Korean subjects. For
the remaining five cSNPs (rs2278008, rs34677, rs2287939,
rs10941112, and rs3195676), the association with prostate can-
cer was analyzed and is summarized in Table 2. Onemissense
SNP (Glu277Lys), rs2278008, was found to be associated with
prostate cancer risk. Individuals with the AG or GG genotype
of rs2278008 revealed to have a lower risk compared to those
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Table 2: Frequency of AMACR (5p13) polymorphisms and association with prostate cancer risk.
SNP Genotype Cases (%) Controls (%) Crude OR (95 %CI) P Adjusted OR (95 %CI)a P 𝑃trend†
rs2278008
A/A 145 (74.7) 109 (64.9) Ref. Ref. 0.0407
A/G 47 (24.2) 56 (33.3) 0.63 (0.40–1.00) 0.0500 0.51 (0.29–0.91) 0.0220
G/G 2 (1.0) 3 (1.8) 0.50 (0.08–3.05) 0.4535 0.42 (0.06–2.99) 0.3892
A/G + G/G 49 (25.3) 59 (35.1) 0.62 (0.40–0.98) 0.0415 0.51 (0.29–0.89) 0.0178
A allele 337 (86.9) 274 (81.5) Ref. Ref.
G allele 51 (13.1) 62 (18.5) 0.67 (0.45–1.00) 0.0506 0.57 (0.35–0.93) 0.0251
rs34677
G/G 143 (73.7) 123 (73.2) Ref. Ref. 0.8638
G/T 46 (23.7) 43 (25.6) 0.92 (0.57–1.49) 0.7343 1.27 (0.66–2.42) 0.4761
T/T 5 (2.6) 2 (1.2) 2.15 (0.41–11.27) 0.3656 1.81 (0.25–12.93) 0.5559
G/T + T/T 51 (26.3) 45 (26.8) 0.97 (0.61–1.56) 0.9149 1.30 (0.70–2.44) 0.4069
G allele 332 (85.6) 289 (86.0) Ref. Ref.
T allele 56 (14.4) 47 (14.0) 1.04 (0.68–1.58) 0.8644 1.30 (0.74–2.27) 0.3656
rs2287939
C/C 149 (76.8) 124 (73.8) Ref. Ref. 0.7474
C/T 39 (20.1) 41 (24.4) 0.79 (0.48–1.30) 0.3587 0.66 (0.36–1.23) 0.1935
T/T 6 (3.1) 3 (1.8) 1.66 (0.41–6.79) 0.4777 0.78 (0.14–4.21) 0.7681
C/T + T/T 45 (23.2) 44 (26.2) 0.85 (0.53–1.37) 0.5095 0.67 (0.37–1.22) 0.1938
C allele 337 (86.9) 289 (86.0) Ref. Ref.
T allele 51 (13.1) 47 (14.0) 0.93 (0.61–1.43) 0.7403 0.72 (0.43–1.22) 0.2268
rs10941112
G/G 69 (35.6) 76 (45.2) Ref. Ref. 0.2155
G/A 96 (49.5) 66 (39.3) 1.60 (1.02–2.52) 0.0410 1.52 (0.86–2.70) 0.1514
A/A 29 (14.9) 26 (15.5) 1.23 (0.66–2.29) 0.5164 1.24 (0.56–2.76) 0.5979
G/A + A/A 125 (64.4) 92 (54.8) 1.50 (0.98–2.28) 0.0616 1.44 (0.85–2.47) 0.1779
G allele 234 (60.3) 218 (64.9) Ref. Ref.
A allele 154 (39.7) 118 (35.1) 1.22 (0.90–1.65) 0.2055 1.21 (0.82–1.79) 0.3273
rs3195676
G/G 69 (35.9) 74 (44.0) Ref. Ref. 0.2955
G/A 94 (49.0) 68 (40.5) 1.48 (0.94–2.33) 0.0883 1.40 (0.79–2.48) 0.2553
A/A 29 (15.1) 26 (15.5) 1.20 (0.64–2.23) 0.5728 1.19 (0.53–2.66) 0.6729
G/A + A/A 123 (64.1) 94 (56.0) 1.40 (0.92–2.14) 0.1172 1.34 (0.78–2.29) 0.2849
G allele 232 (60.4) 216 (64.3) Ref. Ref.
A allele 152 (39.6) 120 (35.7) 1.18 (0.87–1.60) 0.2856 1.16 (0.79–1.72) 0.4404
SNP: single nucleotide polymorphisms; OR: odds ratio; CI: confidence interval; AMACR: (R)-alpha-methyl-CoA racemase.
aAdjusted for age, smoking quantity, alcohol drinking, and family history of prostate cancer.
†Cochran-Armitage trend test for the number of variant alleles.
with the AA genotype (adjusted OR, 0.51; 95% CI, 0.29–
0.89, 𝑃 = 0.018). Also, comparison of the allele frequencies
showed a statistically significant higher frequency of G allele
in the control group than the case group, indicating that the
G allele was associated with a lower risk of prostate cancer
than the A allele (adjusted OR, 0.57: 95% CI, 0.35–0.93, 𝑃 =
0.025). One other cSNP (G175D), rs10941112, also showed
a significant association for the GA genotype which was
evident by an increased prostate cancer risk (OR, 1.60; 95%
CI, 1.02–2.52, 𝑃 = 0.041), although it was no more significant
after adjustment. No significant evidence of prostate cancer
association with the remaining SNPs was identified.
3.3. Association of the AMACR Polymorphism with Clinical
Factors of Prostate Cancer. Reclassifying the patients into
two groups according to their GS produced 95 patients
(49.0%) with GS ≥ 7 and 99 patients (51.0%) with GS < 7.
Interestingly, for patients withGS≥ 7, the GA orAA genotype
of rs10941112 and rs3195676 showed statistically significant
association with increased risk of prostate cancer with an
adjusted OR of 2.28 (𝑃 = 0.010) and 2.35 (𝑃 = 0.008),
respectively, (Table 3). The same genotypes of these cSNPs
were also associated with an increased risk of prostate cancer
with statistical significance for the patients with pTstage ≥
pT2c (adjusted OR 2.60, 𝑃 = 0.007 for rs10941112 and an
adjusted OR of 2.66, 𝑃 = 0.006 for rs3195676).
3.4. AMACR Polymorphisms and Risk of Prostate Cancer with
Amacr Expression. For the case group, AMACR expression
in tumor tissues was determined by immunostaining and
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Table 4: Association analysis of AMACR (5p13) polymorphisms with AMACR expressing prostate cancer risk.
SNP Genotype Cases (%) Controls (%) Crude OR (95%CI) P Adjusted OR (95%CI)a P 𝑃trend†
rs2278008
A/A 120 (77.9) 109 (64.9) Ref. Ref. 0.0088
A/G 33 (21.4) 56 (33.3) 0.54 (0.32–0.88) 0.0147 0.48 (0.26–0.89) 0.0207
G/G 1 (0.6) 3 (1.8) 0.30 (0.03–2.95) 0.3040 0.37 (0.04–3.92) 0.4091
A/G + G/G 34 (22.1) 59 (35.1) 0.52 (0.32–0.86) 0.0104 0.47 (0.26–0.87) 0.0167
A allele 246 (87.9) 274 (81.5) Ref. Ref.
G allele 34 (12.1) 62 (18.5) 0.61 (0.39 –0.96) 0.0327 0.59 (0.34–1.02) 0.0598
rs34677
G/G 113 (73.4) 123 (73.2) Ref. Ref. 0.7336
G/T 36 (23.4) 43 (25.6) 0.91 (0.55 –1.52) 0.7217 1.33 (0.66–2.67) 0.4217
T/T 5 (3.2) 2 (1.2) 2.72 (0.52–14.29) 0.2373 2.28 (0.29–8.15) 0.4354
G/T + T/T 41 (26.6) 45 (26.8) 0.99 (0.60–1.63) 0.9738 1.40 (0.71–2.73) 0.3300
G allele 239 (85.4) 289 (86.0) Ref. Ref.
T allele 41 (14.6) 47 (14.0) 1.05 (0.67–1.66) 0.8169 1.35 (0.72–2.50) 0.3479
rs2287939
C/C 122 (79.2) 124 (73.8) Ref. Ref. 0.2589
C/T 30 (19.5) 41 (24.4) 0.74 (0.44–1.27) 0.2763 0.72 (0.37–1.38) 0.3207
T/T 2 (1.3) 3 (1.8) 0.68 (0.11–4.13) 0.6728 0.50 (0.05–4.88) 0.5550
C/T + T/T 32 (20.8) 44 (26.2) 0.74 (0.44–1.24) 0.2542 0.70 (0.37–1.33) 0.2775
C allele 247 (88.2) 289 (86.0) Ref. Ref.
T allele 33 (11.8) 47 (14.0) 0.82 (0.51–1.32) 0.4186 0.79 (0.44–1.42) 0.4274
rs10941112
G/G 58 (37.7) 76 (45.2) Ref. Ref. 0.4154
G/A 74 (48.1) 66 (39.3) 1.47 (0.91–2.37) 0.1134 1.45 (0.79–2.66) 0.2322
A/A 22 (14.3) 26 (15.5) 1.11 (0.57–2.15) 0.7601 1.08 (0.45–2.57) 0.8655
G/A + A/A 96 (62.3) 92 (54.8) 1.37 (0.88–2.13) 0.1688 1.35 (0.76–2.38) 0.3041
G allele 107 (38.2) 118 (35.1) Ref. Ref.
A allele 173 (61.8) 218 (64.9) 1.14 (0.82–1.59) 0.4271 1.12 (0.73–1.71) 0.6157
rs3195676
G/G 58 (37.9) 74 (44.0) Ref. Ref. 0.5202
G/A 73 (47.7) 68 (40.5) 1.37 (0.85–2.21) 0.1959 1.34 (0.73–2.46) 0.3503
A/A 22 (14.4) 26 (15.5) 1.08 (0.56–2.10) 0.8211 1.03 (0.43–2.46) 0.9503
G/A + A/A 95 (62.1) 94 (56.0) 1.29 (0.82–2.02) 0.2646 1.25 (0.71–2.22) 0.4360
G allele 106 (38.1) 120 (35.7) Ref. Ref.
A allele 172 (61.9) 216 (64.3) 1.11 (0.80–1.54) 0.5364 1.07 (0.70–1.64) 0.7577
SNP: single nucleotide polymorphisms; OR: odds ratio; CI: confidence interval.
aAdjusted for age, smoking quantity, alcohol drinking, and family history of prostate cancer.
†Cochran-Armitage trend test for the number of variant alleles.
reclassified into two subgroups according to expression level:
a negative group (score 0) versus a positive group (score 1+,
2+ or 3+). There were 39 cases (20.2%) in the negative group
and 154 cases (79.8%) in the positive group (Table 1). Between
variants of AMACR and intensity of AMACR expression, no
significant relation was found except for rs2287939 (Supple-
mental Table 4). In the case group expressing AMACR pro-
tein, individuals with the AG or GG genotype of rs2278008
showed a decreased prostate cancer risk compared to those
with the AA genotype (adjusted OR 0.47; 95% CI, 0.26–0.87,
𝑃 = 0.017; Table 4 and supplemental figure).
Considering the clinical features, the AG or GG genotype
of rs2278008 showed a significantly decreased risk of prostate
cancer with GS ≥ 7 (adjusted OR 0.43; 95% CI, 0.19–0.99,
𝑃 = 0.048). Additionally, the GT or TT genotype of rs34677
was associated with a statistically significant decreased risk
for patients with ≥pT2c (adjusted OR 0.35; 95% CI, 0.15–
0.79, 𝑃 = 0.012). Also, the patients with GA or AA genotype
of rs10941112 and rs3195676 revealed to have a significantly
increased risk of developing unfavorable prostate cancer with
≥pT2c (Table 5).
3.5. Haplotype Analysis of AMACRPolymorphism. Thewhole
frequency distribution and association analysis of haplotypes
for SNPs in AMACR are summarized in Table 6 (in Supple-
mental Table 5). When the haplotypes consisted of all five
cSNPs, individuals with the 12345-5 [GGCGG] haplotype
showed a significantly lower risk of prostate cancer compared
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Table 6: AMACR (5p13) haplotypes and their association with prostate cancer risk.
Haplotype∗ Cases (%) Controls (%) Crude OR (95% CI) P value Adjusted OR(95% CI)a P value
12345-1[AGCAA] 147 (37.9) 116 (34.3) Ref. Ref.
12345-2[AGCGG] 116 (29.9) 103 (30.5) 0.89 (0.62–1.27) 0.5208 0.95 (0.60–1.50) 0.8205
12345-3[ATCGG] 56 (14.4) 47 (13.9) 0.94 (0.60–1.49) 0.7919 1.14 (0.62–2.10) 0.6743
12345-4[GGTGG] 33 (8.5) 39 (11.5) 0.67 (0.40–1.13) 0.1306 0.59 (0.31–1.13) 0.1108
12345-5[GGCGG] 11 (2.8) 20 (5.9) 0.43 (0.20–0.94) 0.0348 0.41 (0.17–1.00) 0.0489
12345-6[AGTGG] 18 (4.6) 9 (2.7) 1.58 (0.68–3.64) 0.2849 0.97 (0.35–2.74) 0.9603
12345-7[GGCAA] 7 (1.8) 3 (0.9) 1.84 (0.47–7.28) 0.3839 1.54 (0.28–8.36) 0.6190
Haplotype pair
12-2 [GG]
0 copies 145 (74.7) 110 (65.1) Ref. Ref.
1 or 2 copies 49 (25.3) 59 (34.9) 0.63 (0.40–0.99) 0.0455 0.51 (0.29–0.90) 0.0199
14-3 [GG]
0 copies 153 (78.9) 112 (66.3) Ref. Ref.
1 or 2 copies 41 (21.1) 57 (33.7) 0.53 (0.33 –0.84) 0.0074 0.43 (0.24–0.77) 0.0047
15-3 [GG]
0 copies 150 (77.3) 112 (66.3) Ref. Ref.
1 or 2 copies 44 (22.7) 57 (33.7) 0.58 (0.36–0.92) 0.0197 0.47 (0.27 –0.84) 0.0104
145-3 [GGG]
0 copies 150 (77.3) 112 (66.3) Ref. Ref.
1 or 2 copies 44 (22.7) 57 (33.7) 0.58 (0.36–0.92) 0.0197 0.47 (0.27 –0.84) 0.0104
1245-4 [GGGG]
0 copies 151 (77.8) 113 (66.9) Ref. Ref.
1 or 2 copies 43 (22.2) 56 (33.1) 0.57 (0.36–0.92) 0.0199 0.48 (0.27 –0.86) 0.0132
1345-4 [GCGG]
0 copies 182 (93.8) 148 (87.6) Ref. Ref.
1 or 2 copies 12 (6.2) 21 (12.4) 0.46 (0.22–0.98) 0.0428 0.40 (0.17–0.95) 0.0379
12345-5 [GGCGG]
0 copies 183 (94.3) 149 (88.2) Ref. Ref.
1 or 2 copies 11 (5.7) 20 (11.8) 0.45 (0.21–0.96) 0.0400 0.41 (0.17–0.99) 0.0472
Haplotypes with total frequencies of less than 1 percent were excluded in table.
OR: odds ratio; CI: confidence interval; AMACR: (R)-alpha-methyl-CoA racemase.
∗1: rs2278008; 2: rs34677; 3: rs2287939; 4: rs10941112; 5: rs3195676.
aAdjusted for age, smoking quantity, alcohol drinking, and family history of prostate cancer.
to the subjects with the most frequent haplotype 12345-
1 [AGCAA] (adjusted OR, 0.41; 95% CI, 0.17–1.00, 𝑃 =
0.049). Furthermore, individuals with one or more copies
of the [GGCGG] tended to have a significantly decreased
risk of prostate cancer compared to those without [GGCGG]
haplotype (adjusted OR, 0.41; 95% CI, 0.17–0.99, 𝑃 = 0.047).
Interestingly, when we considered the haplotype pair of each
individual, the haplotype pair harboring the G allele of SNP
rs2278008 revealed a lowered risk in combination with the G
allele of rs34677, rs1094112, and rs3195676 (Table 6).
4. Discussion
AMACR is a key enzyme in the ß-oxidation catabolic
pathway of fatty acids and is known to be upregulated in
several cancers including prostate cancer [23–26]. Sequence
variants of AMACR have been previously investigated to find
their association with prostate cancer risk [10–12, 27, 28].
Results, however, were inconsistent: One study suggested
that variants in AMACR gene were associated with familial,
but not sporadic, prostate cancer [10] and other subsequent
studies reported no association between sporadic prostate
cancer and AMACR gene variants [18, 19] (http://dceg
.cancer.gov/research/how-we-study/genomic-studies/cgems-
summary/). In the subgroup analysis of one of these studies, a
tendency toward decreased risk in homozygouswhite carriers
of the variant alleles for both rs3195676 and rs10941112 was
evident [19]. Thus, genetic studies about the association of
genetic polymorphisms with prostate cancer risk might show
different results depending on the ethnic background of the
subjects. The use of Korean men, who are reported as an
ethnically homogenous population [21], may deliver useful
conclusion for the association of AMACR polymorphisms
with prostate cancer risk, by reducing the possible influences
related to genetic heterogeneity. Here, we found statistically
significant association of AMACR polymorphisms with
prostate cancer risk using single ethnic Koreans without any
family history of immigration from other countries. Further,
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we analyzed the risk of prostate cancer in relation with
AMACR polymorphism in cases of AMACR expression.
In our study, rs2278008 (E277K) was associated with
prostate cancer risk in ethnically homogenous Koreans with
statistical significance. To our knowledge, this is the first
report of a protective effect of rs2278008 of the AMACR gene
on the development of sporadic prostate cancer. Although,
rs2278008 SNP of AMACR was reported previously with the
significantly different genotype frequencies between heredi-
tary prostate cancer groups and controls, this tendency was
not shown when compared with a sporadic prostate can-
cer group [10]. In our study, the GG or AG genotype of
rs2278008wasmore frequently observed in the control group
when compared with the sporadic prostate cancer group.
Furthermore, in subjects expressing AMACR, the association
of rs2278008 with prostate cancer risk also showed statistical
significance. With respect to the association of the gene vari-
ant with clinical factors of prostate cancer, recent data as part
of the Michigan Prostate Cancer Genetics Project demon-
strated a significant linkage betweenmarkers on 5p13-q11 and
prostate cancer aggressiveness, as defined by GS [29]. These
observations suggest that this region of the genome may
harbor sequence variations associated with prostate cancer
risk and the extent of tumor differentiationmay be considered
as a predictor for prognosis. We also found genetic variations
of AMACR related to the histologic grade of prostate cancer.
Patients with a specific sequence variant of rs2278008 and
rs34677 tended to show a decreased risk of developing
unfavorable prostate cancer with GS ≥ 7 or ≥pT2c. On
the contrary, patients with the GA or AA genotype of
rs10941112 and rs3195676 displayed a significantly increased
risk of developing unfavorable prostate cancer. Based on this
result, the genetic polymorphism of AMACRmight influence
the development of prostate cancer for patients expressing
AMACR. Additionally, haplotype analysis revealed the com-
binatorial impact of individual SNPs clearly. The protective
effect of rs2278008may strongly influence cancer susceptibil-
ity with the risk decreased by the effect of rs34677, rs10941112,
or rs3195676, since the G allele of rs2278008 was mostly
revealed as statistically significant and the protective effects
in any combination with G allele of rs34677, rs10941112, or
rs3195676, but protective effects were not present with the
others. This is the first report ever for the analysis of the
combinatorial effect of AMACR SNPs on the prostate cancer
susceptibility in haplotype.
Unlike other cancers, prostate cancer cells use fatty acid as
theirmain energy source instead of glucose [30–32]. AMACR
is required to enter into the fatty acid oxidation, resulting in
energy production for the cancer cells [30, 31]. Combining
our discovery (the protective role of rs2278008 in AMACR),
the missense mutation by the minor allele of the sequence
variant might disrupt or decrease the enzyme (AMACR)
activity, subsequently leading to unfavorable energy supply
in the cancer cells. The speculation can explain the lower
prostate cancer risk for the missense mutation-harboring
patients, which needs to be further studied. In addition,
three-dimensional structural data implicate that the substitu-
tion encoded by rs1094112 (G175D) may directly impact the
stability of the AMACR protein backbone [33]. Otherwise,
no studies have investigated the impact of genetic variations
on characteristics of prostate cancer by changing functional
structure.
Despite the new findings that the sequence variants of
AMACR are related to the risk of sporadic prostate cancer
in the ethnically homogenous population of Korean men,
caution should be taken when interpreting our findings due
to some limitations. Firstly, because of the relatively small
number of cases and controls in this study, the power of this
study is limited. Particularly, stratified analyses with respect
to clinical factors of prostate cancer might be underpowered.
By using PGA method, the SNPs in our study were were
calculated about 5%∼ about 43% power at an 𝜎 value of 5%,
although it has low power, and statistically significant finding
was detected. Instead of each value for statistical power, we
just presented wide range of statistical power because of
many subgroups including clinical factors of prostate cancer.
Secondly, the patients were older and consumed less alcohol
than the controls, and the number of patients having a family
history of prostate cancer (not first-degree relatives)wasmore
than the controls, although it was not statistically significant.
To minimize the effect of the different distribution in cases
and controls, we adjusted the age, smoking quantity, alcohol
drinking, and family history of prostate cancer in statistical
analysis. Furthermore, our primary interest lay in the geno-
type and its association with prostate cancer risk, and it is
unlikely that the genotype is affected by age. Thus, we believe
that the bias possibly caused by different age distributions
among cases and controls would minimally influence for the
results of our study.
5. Conclusions
We concluded that the genetic variations of AMACR were
associated with the risk of sporadic prostate cancer treated
with radical prostatectomy in ethnically homogenous pop-
ulation of Korean men. Our investigation of the relation-
ship between genotype frequencies, haplotype pair, and the
expression of AMACR protein in tumors with clinical fea-
tures demonstrates that sequence variants of AMACR may
play an important role in the development of prostate cancer.
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